Skip to Main Content

Paper Details

MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer.
Pathol Oncol Res
3
2022
500 genes, CAPZA2, CAV1, CFTR, HLA-DRB1, LRRD1, MET, MET fusion, MET gene, MET gene fusion, MET proto-oncogene, MET proto-oncogene receptor tyrosine, MET-amplified cancers, MET-amplified tumors, PCM1, PD-L1, Partner genes, Programmed death-ligand 1, ST7, TFEC, advanced cancer, advanced solid, advanced solid tumors, cancer, colorectal, gastric, oncology, patients, patientswith, receptor tyrosine kinase gene, sarcoma, tumors, tyrosine
Author NameAffiliation
Sung Tae KimSamsung Medical Center, Sungkyunkwan University
Sung Tae KimSamsung Medical Center, Sungkyunkwan University
Joon Oh ParkSamsung Medical Center, Sungkyunkwan University
Kyoung-Mee KimSamsung Medical Center, Sungkyunkwan University
Jeeyun LeeSamsung Medical Center, Sungkyunkwan University
  • 1 - 5

Datasets

Release 1.2